American Association for Cancer Research
Browse
19406207capr150077-sup-145792_2_supp_3085858_nslklj.xlsx (10.38 kB)

Supplementary Table 1 from MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas

Download (10.38 kB)
dataset
posted on 2023-04-03, 19:23 authored by Ayumu Taguchi, Jung-hyun Rho, Qingxiang Yan, Yuzheng Zhang, Yang Zhao, Hanwen Xu, Satyendra Chandra Tripathi, Hong Wang, Dean E. Brenner, Melanie Kucherlapati, Raju Kucherlapati, Adam T. Boutin, Y. Alan Wang, Ronald A. DePinho, Ziding Feng, Paul D. Lampe, Samir M. Hanash

Subject demographics in the University of Michigan sample set

History

ARTICLE ABSTRACT

Blood-based biomarkers for early detection of colorectal cancer could complement current approaches to colorectal cancer screening. We previously identified the APC-binding protein MAPRE1 as a potential colorectal cancer biomarker. Here, we undertook a case–control validation study to determine the performance of MAPRE1 in detecting early colorectal cancer and colon adenoma and to assess the potential relevance of additional biomarker candidates. We analyzed plasma samples from 60 patients with adenomas, 30 with early colorectal cancer, 30 with advanced colorectal cancer, and 60 healthy controls. MAPRE1 and a set of 21 proteins with potential biomarker utility were assayed using high-density antibody arrays, and carcinoembryonic antigen (CEA) was assayed using ELISA. The biologic significance of the candidate biomarkers was also assessed in colorectal cancer mouse models. Plasma MAPRE1 levels were significantly elevated in both patients with adenomas and patients with colorectal cancer compared with controls (P < 0.0001). MAPRE1 and CEA together yielded an area under the curve of 0.793 and a sensitivity of 0.400 at 95% specificity for differentiating early colorectal cancer from controls. Three other biomarkers (AK1, CLIC1, and SOD1) were significantly increased in both adenoma and early colorectal cancer patient plasma samples and in plasma from colorectal cancer mouse models at preclinical stages compared with controls. The combination of MAPRE1, CEA, and AK1 yielded sensitivities of 0.483 and 0.533 at 90% specificity and sensitivities of 0.350 and 0.467 at 95% specificity for differentiating adenoma and early colorectal cancer, respectively, from healthy controls. These findings suggest that MAPRE1 can contribute to the detection of early-stage colorectal cancer and adenomas together with other biomarkers. Cancer Prev Res; 8(11); 1112–9. ©2015 AACR.

Usage metrics

    Cancer Prevention Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC